Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
arcticnovartis
- Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site
- New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
- First to have delivered at scale, Novartis fortifies leadership in RLT innovation and infrastructure with California facility, additional plans for Florida and Texas